Document:

Exhibit 10.35

 

Board
of Directors Agreement

 

July
23, 2021

 

Name:
Maria Vilenchik

Address:
45 Ridge rd

Waban,
MA 02468

 

Dear
Maria:

 

On
behalf of Felicitex Therapeutics, Inc. (the “Company”), I am pleased to offer you a position on our Board of Directors for
a three year term subject to annual approval of the shareholders.

 

Subject
to the approval of the Company’s Board of Directors, you will be granted a non-qualified option to purchase 30,000 shares of Company
common stock under the Company’s 2012 Stock Option and Restricted Stock Plan at an exercise price equal to the fair market value
of that stock on your option grant date, as determined in good faith by the Company’s Board of Directors. Subject to your acceptance
of this agreement, your option will vest over a period of three years subject to your continued service on the Board of Directors or
as a consultant to the Company. Your option will be subject to the terms and conditions of the Company’s 2012 Stock Option and
Restricted Stock Plan and standard form of stock option agreement, which you will be required to sign as a condition of receiving the
option.

 

As
a Director, you will be invited to attend Directory Board Meetings, either in person or on the phone, which will be arranged on an as
needed basis (no more than four per year). In addition, your name and bio will appear on our website and materials in the Director section.
Your service as an Director will be subject to the Company’s Board of Directors Terms and Conditions attached hereto as Exhibit
A (the “Terms”), to which you agree by your signature below.

 

On
behalf of all of the Company’s management, we are excited about you serving on the Board of Directors for the Company, and we look
forward to your input and guidance.

 

	 	Sincerely,
	 	 
	 	Felicitex Therapeutics, Inc.
	 	 	 
	 	By:	/s/ Marc Duey
	 	 	Marc Duey, Chairman

 

I
agree to and accept the Board of Directors position and agree to be bound by the Terms.

 

	Date: July 23, 2021	/s/ Maria Vilenchik
	 	Maria Vilenchik,
PhD

 

    1

    	

    

 

Exhibit
A

BOARD
OF DIRECTORS TERMS AND CONDITIONS

 

	1.	EXPENSES

 

The
Company shall reimburse Director in accordance with the Company’s policies for reasonable travel and related expenses incurred
in the course of performing services hereunder, provided that appropriate documentation of such expenses must be provided in accordance
with such policies. Further expenses in excess of $300 must be approved in advance by the Company before any such expense is incurred.
Director shall not otherwise be paid for the collaboration, advice and assistance provided to the Company in connection with service
on the Board of Directors (the “Services”).

 

	2.	TERMINATION

 

Director’s
service on the Board of Directors may be terminated by either party for any reason upon written notice to the other party.

 

	3.	INDEPENDENT
                                            CONTRACTOR

 

Director’s
relationship with the Company will be that of an independent contractor and not that of an employee. Director has no authority to enter
into contracts that bind the Company or create obligations on the part of the Company without the prior written authorization of the
Company.

 

	4.	NONDISCLOSURE
                                            OF CONFIDENTIAL INFORMATION

 

		A.	Definition
                                            of Confidential Information. “Confidential Information” means
                                            any information, technical data or know-how (whether disclosed before or after the date of
                                            this Agreement), including, but not limited to, information relating to business and product
                                            or service plans, financial projections, customer lists, business forecasts, sales and merchandising,
                                            human resources, patents, patent applications, computer object or source code, research,
                                            inventions, processes, designs, drawings, engineering, marketing or finance to be confidential
                                            or proprietary or which information would, under the circumstances, appear to a reasonable
                                            person to be confidential or proprietary. Confidential Information does not include information,
                                            technical data or know-how which: (i) is in the possession of Director at the time of disclosure,
                                            as shown by Director’s files and records immediately prior to the time of disclosure;
                                            or (ii) becomes part of the public knowledge or literature, not as a direct or indirect result
                                            of any improper inaction or action of Director.

 

		B.	Agreement
                                            Not to Disclose. Director agrees not to use any Confidential Information disclosed
                                            to Director by the Company for Director’s own use or for any purpose other than to
                                            carry out discussions concerning, and the undertaking of, the Services. Director shall not
                                            disclose or permit disclosure of any Confidential Information of the Company to third parties
                                            other than other members of the Company’s Board of Directors. Director agrees to take
                                            all reasonable measures to protect the secrecy of and avoid disclosure or use of Confidential
                                            Information of the Company in order to prevent it from falling into the public domain or
                                            the possession of persons other than those persons authorized under this Agreement to have
                                            any such information. Director further agrees to notify the Company in writing of any actual
                                            or suspected misuse, misappropriation or unauthorized disclosure of the Company’s Confidential
Information which may come to Director’s attention.

 

		C.	Exceptions.
                                            Notwithstanding the above, Director shall not have liability to the Company or any of its
                                            subsidiaries with regard to any Confidential Information of the Company which Director can
                                            prove (i) is disclosed with the prior written approval of the Company, or (ii) is disclosed
                                            pursuant to the order or requirement of a court, administrative agency, or other governmental
                                            body; provided, however, that Director shall provide prompt notice of such court order or
                                            requirement to the Company to enable the Company
or its appropriate subsidiary to seek a protective order or otherwise prevent or restrict such disclosure.

 

    1

    	

    

 

	5.	NO
                                            DUPLICATION; RETURN OF MATERIALS

 

Director
agrees, except as otherwise expressly authorized by the Company, not to make any copies or duplicates of any the Company’s Confidential
Information. Any materials or documents that have been furnished by the Company to Director in connection with the Services shall be
promptly returned by Director to the Company, accompanied by all copies of such documentation, within ten days after (a) the Services
have been concluded or (b) the written request of the Company.

 

	6.	NO
                                            RIGHTS GRANTED

 

Nothing
in this Agreement shall be construed as granting any rights under any patent, copyright or other intellectual property right of the Company,
nor shall this Agreement grant Director any rights in or to the Company’s Confidential Information, except the limited right to
use the Confidential Information in connection with the Services.

 

	7.	ASSIGNMENT
                                            OF INVENTIONS

 

To
the extent that, in the course of performing the Services, Director jointly or solely conceives, develops, or reduces to practice any
inventions, original works of authorship, developments, concepts, know-how, improvements or trade secrets, whether or not patentable
or registrable under copyright or similar laws, Director hereby agrees to assign all rights, titles and interest to such inventions to
the Company.

 

	8.	DUTY
                                            TO ASSIST

 

As
requested by the Company, Director shall take all steps reasonably necessary to assist the Company in obtaining and enforcing in its
own name any patent, copyright or other protection which the Company elects to obtain or enforce for its inventions, original works of
authorship, developments, concepts, know-how, improvements and trade secrets. Director’s obligation to assist the Company in obtaining
and enforcing patents, copyrights and other protections shall continue beyond the termination of Director’s relationship with the
Company, but the Company shall compensate Director at a reasonable rate after the termination of such relationship for time actually
spent at the Company’s request providing such assistance.

 

	9.	DUTY
                                            OF CARE

 

Duty
of care is a fiduciary responsibility for company directors that requires them to make decisions in good faith and in a reasonably prudent
manner. The duty of care requires directors to make business decisions after taking all available information into account, and then
act in a judicious manner that promotes the company’s best interests. Directors are required to exercise the utmost care in making business
decisions in order to fulfill their fiduciary duty.

 

	10.	DUTY
                                            OF LOYALTY

 

The
duty of loyalty requires a director to be completely loyal to the company at all times. It also imposes the responsibility to avoid possible
conflicts of interest, thereby precluding a director from self-dealing or taking advantage of a corporate opportunity for personal gain.

 

	11.	NO
                                            CONFLICTS

 

Director
represents that Director’s compliance with the terms of this Agreement and provision of Services hereunder will not violate
any duty which Director may have to any other person or entity (such as a present or former employer), including obligations
concerning providing services to others, confidentiality of proprietary information and assignment of inventions, ideas, patents or
copyrights. Director agrees that Director will not do anything in the performance of Services hereunder that would violate any such
duty. In addition, Director agrees that prior to performing any services for or otherwise participating in a company developing or
commercializing new services, methods or devices that may be competitive with the Company, Director shall first notify the Company
in writing of any potential conflicts. It is understood that in such event, the Company will review whether Director’s
activities are consistent with Director remaining a member of the Company’s Directory Board.

 

	12.	MISCELLANEOUS

 

Any
term of these Terms may be amended or waived only with the written consent of the parties. The Director Agreement and these Terms constitute
the sole agreement of the parties and supersede all oral negotiations and prior writings with respect to the subject matter hereof. The
validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the Commonwealth of Pennsylvania.

 

 

2Exhibit 10.36

 

**THIS
EXHIBIT HAS BEEN REDACTED TO REMOVE INFORMATION THAT IS NOT MATERIAL AND THAT THE REGISTRANT MUST TREAT AS PRIVATE AND CONFIDENTIAL.**

 

FELICITEX MATERIAL TRANSFER
AGREEMENT

 

This Felicitex
Material Transfer Agreement (this “Agreement”) is dated May 15th, 2021 and is by and between Felicitex
Therapeutics, Inc., a Delaware corporation (“Felicitex”) at 27 Strathmore Rd., Natick, MA, USA and UAB DolceRx Baltika
(“DolceRx”), a Lithuanian corporation (“Recipient”) at Pramones str. 21, Klaipeda, Lithuania (together with
Felicitex, “Parties” and each, a “Party”).

 

WHEREAS,
Felicitex possesses certain technical and other proprietary material as detailed below;

 

WHEREAS,
Recipient desires to use the Material for certain research and evaluations as detailed herein; and

 

WHEREAS,
Felicitex desires to share the Material with Recipient, but only in accordance with the terms and conditions of this Agreement.

 

NOW, THEREFORE,
in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the sufficiency of which is
hereby acknowledged, the Parties agree as follows:

 

1. 
The Material. Felicitex shall deliver to Recipient the technical and other proprietary
material and/or information as detailed in Exhibit 1 hereto (the “Material”).

 

2. 
The Purpose. The Recipient shall use the Material only for purposes set out in the study proposal attached hereto
as Exhibit 2 (the “Purpose”) and for no other purpose or use whatsoever. Recipient shall further use the Material
in accordance with directions provided by Felicitex. Felicitex will try to provide the amount of the Material needed to complete the Purpose;
however, Recipient acknowledges that Felicitex is not required to replace lost or damaged Material or any Material deemed to be unfit.
Felicitex cannot guarantee that any additional supply of the Material can be made available in the future or, if available, that it will
be from the same lot or of similar quality.

 

3.  Restrictions
on Use. (a) Recipient shall only allow those trained in handling similar materials in their assigned job functions
to handle the Material. (b) Recipient shall be responsible for ensuring that all personnel utilizing the Material, receiving
Confidential Information (as defined herein), and/or conducting the Purpose understand and agree to be bound by all of the terms and
conditions of this Agreement, and Recipient agrees to be responsible for any failures by personnel to comply with this Agreement.
(c) Recipient assumes all responsibilities and risks in connection with the receipt, handling, storage, use, and disposal of the
Material, and will comply with all applicable federal, state, and local laws and regulations. (d) Recipient understands that the
Material has not been approved for human use and Recipient shall not administer the Material to humans in any manner or form. (e)
Recipient shall not sell, transfer, or otherwise distribute the Material to any third party without expressed written
permission by Felicitex. (f) Recipient shall not allow the Material to be handled or disclosed to any
personnel who do not have a need to know about the Material for the Purpose. (g) Recipient shall not use the Material to support the
research or development of any commercial product except as indicated in the Purpose, including, without limitation,
any product containing, discovered, or derived from use of the Material. (h) Recipient shall not attempt to reverse engineer,
characterize, or ascertain the chemical structure of the Material or its degradants or metabolites, and shall not make derivatives
of, or perform experiments to determine the identity of the Material.

 

     

     

    

 

4. Disclaimer.
RECIPIENT ACKNOWLEDGES THAT THE MATERIAL lS EXPERIMENTAL IN NATURE ANO IS BEING PROVIDED “AS IS’. AND WITHOUT WARRANTY,
EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TOXICITY PROFILE,
AND WARRANTY OF NON-INFRINGEMENT OF ANY PROPRIETARY OR INTELLECTUAL PROPERTY RIGHT OF A THIRD PARTY.

 

5. Reports.
Recipient shall provide Felicitex with a written report detailing its progress on the Purpose and its finding, including relevant know-how,
within fourteen (14) days upon (a) reasonable request from Felicitex from time to time, (b) completion of the Purpose or as scheduled
in Exhibit 2 and (c) termination of this Agreement.

 

6. Confidential
Information. As used herein, “Confidential Information” means this Agreement, the Material, any Results
and Inventions (as defined below), and all information in any form concerning the Material plus other scientific, technical, trade, or
business information that is treated by Felicitex as confidential or proprietary and that is disclosed by Felicitex to Recipient hereunder.
Recipient agrees that Recipient shall (a) use, copy, and make extracts of the Confidential Information only in connection with the Purpose
and (b) not disclose any of the Confidential Information to any third party other than its directors, officers, and employees who have
a need to know the Confidential Information for the Purpose and who are bound by obligations of confidentiality substantially similar
to those in this Agreement. Recipient is liable to Felicitex for any use or disclosure of the Confidential Information in violation of
the terms of this Agreement by any of Recipient’s personnel. The terms of this Section do not apply to any information that Recipient
can demonstrate: (i) Recipient possessed before Felicitex disclosed it under this Agreement; (ii) is or becomes public (other than as
a result of breach of this Agreement by the Recipient or its personnel); (iii) the Recipient obtains from a third party free of any confidentiality
obligation to Felicitex with respect to such information; or (iv) is independently developed by or on behalf of Recipient without the
use of the Confidential Information. Notwithstanding anything to the contrary contained herein, Recipient shall be permitted to disclose
any Confidential Information that is required to be disclosed by a governmental authority or by applicable law, provided that the Recipient
shall: (i) notify Felicitex of any such disclosure requirement as soon as practicable; (ii) cooperate with Felicitex if Felicitex seeks
a protective order or other remedy in respect of any such disclosure; and (iii) furnish only that portion of the Confidential Information
which Recipient is legally required to disclose.

 

 7. Intellectual Property.

 

(a) The
Material and all proprietary rights thereto, including, but not limited to, patent rights, are and shall remain the sole property of Felicitex.
No express or implied license or any other right is granted to Recipient under any patents, patent applications, trade secrets, or other
proprietary rights of Felicitex except for the limited purpose of the Purpose and as set forth herein.

 

     

     

    

 

(b) Any
and all results obtained with the Material and by engaging in the Purpose, including the underlying data and conclusions drawn from
the Purpose (together, with all intellectual property rights therein, the “Results”), and any improvements and
discoveries, whether or not patentable, arising from the use of the Material, including, without limitation, any mixtures or
combinations or conjugates of the Material with other molecules and applications to various indications, (together, with all
intellectual property rights therein, the “Inventions”), shall become the sole property of Felicitex, unless
specified otherwise in Exhibits to this Agreement. Recipient agrees to assign and does hereby assign its entire right, in
whatsoever countries, title, and interest in and to the Results and the Inventions in whatsoever countries, whether patentable or
not, to Felicitex. Recipient shall compel the personnel assigned by Recipient to execute the purpose to assign the entire right, in
whatsoever countries, title, and interest in and to the Results and the Inventions in whatsoever countries, whether patentable or
not, to Felicitex. All personnel assigned by Recipient to execute the Purpose must irrevocably designate and appoint the Recipient
and each of its duly authorized officers and agents as person’s agent and attorney-in-fact to do all lawfully permitted acts
to further the prosecution, issuance, and enforcement of patents or other rights or protection with the same force and effect as if
executed and delivered by personnel, in the event Recipient is unable to secure the signature of any one of Recipient’s
personnel involved in execution of the Purpose on any document necessary or desirable to apply for, prosecute, obtain, or enforce
any patent or other right or protection relating to any Invention covered by this Agreement, due to incapacity or any other
cause.

 

(c) Recipient
shall promptly disclose to Felicitex any and all Results and Inventions and, upon request of Felicitex, sign, execute, and deliver any
and all documents or instruments, including patent applications, declarations, invention assignments, and any and all other applications
in whatsoever countries (including, but not limited to all divisional, renewal, substitute, continuation, continuation-in-part, reissue,
and convention patent applications based in whole or in part upon the Results and/or Inventions, together with the right of priority,
and any and all reissues, reexaminations, and extensions of patent(s) granted for the Results and/or Inventions, and every priority right
that is or may be predicated upon or arise from the Results and/or Inventions) and will take any other action which Felicitex shall deem
necessary to perfect Felicitex’s rights with respect to the Results and the Inventions. Felicitex agrees to pay reasonable out of pocket
fees and expenses incurred by Recipient for any assistance rendered to Felicitex pursuant to this Subsection.

 

8. Publications.

 

(a) Publications,
in print, electronic, or other media, include but are not limited to articles, whether in peer reviewed journal or not, articles,
opinion pieces, testimonials, etc. in trade magazines or pamphlets, books, book chapters, posters, oral presentations, videos, etc.
in English or another language (together “Publications”). If Recipient wishes to publish any of the Results, Recipient
will furnish Felicitex with a copy of the manuscript disclosing such Results prior to submission. Felicitex shall have thirty (30)
days after receipt of the copy to review the proposed publication to provide comments or objections, and to suggest corrections and
amendments in writing for Recipient’s consideration, and/or to remove any Confidential Information. If Felicitex does not
provide any comments within thirty (30) days of receipt of a copy of the proposed publication then the proposed publication is
seemed to be accepted as is. In the event that Felicitex provides Recipient with written comments, objections, corrections, or
amendments to the proposed publication, Recipient shall either (i) make reasonable effort to implement Felicitex’s corrections
and amendments; (ii) remove Confidential Information from the proposed publication; (iii) or, if any Confidential Information
remains in the proposed publication, the Recipient will delay its submission for publication for maximum of sixty (60) days from
receipt of Felicitex’s objections on the proposed publication to allow Felicitex an opportunity to protect Felicitex’s
proprietary or intellectual property rights relating to the Material that might be contained in such disclosure.

 

     

     

    

 

(b) Without
limiting the foregoing, any publication by Recipient wholly or in part based on or related to the Material, the Purpose, the Results,
or the Inventions must list Felicitex’s personnel (scientists or consultants, in the discretion of Felicitex) as co-authors and/or acknowledge
Felicitex as the source of the Material.

 

 9. Termination. Felicitex may terminate Recipient’s right to use the Material upon notice to Recipient at any time. Within fourteen (14) days of termination for any reason, Recipient shall return to Felicitex any of the Material in Recipient’s possession, or, upon Felicitex’s instruction, destroy any such Material and certify in writing that the Recipient has either returned to Felicitex or destroyed all of the Material. Upon termination for any reason, only Recipient’s right to use the Material shall be terminated, and all other parts of this Agreement shall stay in effect. Upon termination for any reason and upon fourteen days (14) of written request by Felicitex, Recipient shall return or destroy all documents or copies containing Confidential Information; provided however that Recipient may retain one copy of such files for archival purposes only.

 

 10. Indemnification and Release. Recipient shall indemnify and hold Felicitex harmless for and against any and all third-party claims and expenses, including attorney’s fees and all other costs, arising from or in connection with Recipient’s use or disposition of the Material and/or this Agreement. In the event that Recipient has a dispute with any third parties arising from or in connection with Recipient’s use or disposition of the Material, Recipient hereby releases Felicitex, its officers, employees, agents, consultants, and successors-in-right from claims, demands, and damages (actual and consequential) of every kind or nature, known and unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to any such dispute.

 

 11. Limitations of Liability. Under no circumstances shall Felicitex be liable to any party (including Recipient) for any direct or any special, incidental, indirect, consequential, exemplary, or punitive damages based on any theory of liability arising out of or in any manner connected with this Agreement, the Material or the subject matter hereof, and regardless of whether Felicitex has been informed of or otherwise may have anticipated the possibility of such damages. Without limiting the foregoing, the total aggregate liability of Felicitex to Recipient arising out of or in any manner connected with this Agreement or the Material shall be limited to [**].  

 

 12. Insurance and Risk. Recipient represents and warrants to Felicitex that it is either self-insured or that it has adequate liability insurance protection to conduct the Purpose, such protection also being applicable to Recipient’s personnel while acting in the scope of their engagement with Recipient. Recipient assumes any and all risks of personal injury, property damage, or any other form of damage or injury attributable to neglect, acts, or omissions of Recipient, its personnel or third parties.

 

     

     

    

 

 13. General Terms.

 

(a) Entire
Agreement; Amendments.This Agreement embodies the entire agreement and understanding of
the Parties with respect to the transactions contemplated by this Agreement. This Agreement supersedes all prior discussions,
negotiations, agreements, and understandings (both written and oral) between the parties with respect to the transactions
contemplated hereby that are not reflected or set forth in this Agreement. This Agreement may only be amended in writing executed by
both parties.

 

(b) Assignment
and Sublicensing. Recipient may not assign, sublicense, or transfer this Agreement without the prior written consent of Felicitex.

 

(c) Successors
and Assigns. All assignments and ownership of the Material, Results, Inventions, etc. inure to Felicitex’s successors, assigns, and
legal representatives. The obligations of confidentiality, assignment of patent rights, etc. inure to Recipient’s successors, assigns,
and legal agents.

 

(d) Severability.
If any provision of this Agreement, or the application of any such provisions to either of the Parties is held by a court of competent
jurisdiction to be invalid, unlawful, or unenforceable, (i) the remaining provisions of this Agreement will nonetheless be valid and enforceable
and shall remain in full force and effect, and will not be affected, impaired, or invalidated in any manner, (ii) such determination shall
not affect the validity, lawfulness, or enforceability of this Agreement in any other jurisdiction, and (iii) the invalid, unlawful, or
unenforceable provision will be deemed superseded by a valid, lawful, and enforceable provision that most closely matches the intent of
the original provision.

 

(e) Third
Parties. Nothing herein is intended, nor will be deemed, to confer rights or remedies upon any third party.

 

(f) Interpretation.
The headings in this Agreement are inserted for convenience of reference only and are not to be considered in the interpretation or construction
of the provisions hereof. The singular of any term shall include the plural, and vice versa. All uses of “including” herein
shall be interpreted to mean “including, but not limited to.”

 

(g) Notices.
All notices hereunder shall be in writing and shall be delivered by certified mail and email to the other party at the address
set forth below or at such other address as such party may designate in writing. Each such notice hereunder will be effective upon the
date of delivery.

 

Felicitex:

 

Attn: Maria
Vilenchik, PhD

 Felicitex Therapeutics, Inc. 

45 Ridge Road

Newton, MA 02468

mvilenchik@felicitex.com

 

With a copy to:

 

Val Gurvits, Esq.

 Boston Law Group,
PC

825 Beacon Street, Suite 20

Newton Centre, MA 02459

vgurvits@bostonlawgroup.com

 

     

     

    

 

Recipient:

 

Attn: Olga Potapova, PhD, Direktore

 UAB DolceRx Baltika

olga-potapova@cureline.com

 

With a copy to:

 

Agne Vaitkeviciene, CEO

UAB DolceRx Baltika

agne@cureline.com

 

(h) Governing
Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts
without regard to the conflict of law principles thereof. The parties agree to the exclusive jurisdiction of the state and federal courts
in Boston, Massachusetts.

 

(i) Counterparts.
This Agreement may be executed in two counterparts, each of which, when so executed and delivered, shall be an original, but both of which
together shall constitute one and the same instrument.

 

(j)
Language. If this Agreement is executed in English and any other language, in the event of a conflict between the English version
and the foreign translation, the terms of the English version shall control.

 

(k) Waiver.
Any waiver by either Party of any right shall not operate or be construed as a general waiver.

 

[Signatures on next page]

 

     

     

    

 

IN WITNESS WHEREOF, the undersigned
Parties have executed this Agreement as of the date set forth above.

 

	FELICITEX:	 
	Felicitex Therapeutics, Inc.	 
	 	 
	By: 	/s/ Maria Vilenchik	 
	Name: 	Maria Vilenchik, PhD	 
	Title: 	Founder & CEO	 
	 	 	 
	RECIPIENT:	 
	UAB DolceRx Baltika	 
	 	 
	By: 	/s/ Agne Vaitkeviciene	 
	Name:  	Agne Vaitkeviciene	 
	Title: 	CEO	 

 

     

     

    

 

Exhibit 1

The Material

 

Felicitex Therapeutics Inc. shall deliver the following
compounds:

 

	Compound	Amount	Details
	FX7742
    (SLV series)	[**]	PK/PD
    and MTD is completed by Felicitex Therapeutics Inc.
	FX
    1610 (DHT series)	[**]
	FX8474
    (SLV series)	[**]	TBD

 

1.
For [**] studies, the administration of test articles and the number of animals in each study group are shown in Table 2. For
groups 1 to 5, dosing will start when [**]. Body weights
and glucose levels will be monitored throughout. Livers and pancreas
will be removed at termination (from n=3 animals per group) and formalin fixed in all groups. Pancreas will be analyzed for DyrklB,[**].
Serum will be harvested from animals dosed with FX but that reached the termination endpoint.

 

Table 2. Study 1 Design

 

	Group	N	Treatment	Dose

 Level	Dosing

 Route	Schedule	Readout	Pancreas IHC Readout
	1	12	PBS	--	i.p.	Day 1, QD 5 days	glucose GTT body weight survival	DYRK1B
	2	12	STZ	[**]	i.p.	Day 1, QD 5 days	glucose GTT body weight survival	DYRK1B
	3	12	STZ	[**]	i.p.	Day 1, QD 5 days	glucose GTT body weight survival	DYRK1B
	Insulin	Dose 1	i.p.	*Day 12, QD 7 days
	4	12	STZ	[**]	i.p.	Day 1, QD 5 days	glucose GTT body weight survival	DYRK1B
	FX1610	Dose 2	i.p.	*Day 12, QD 7 days
	5	6	STZ	[**]	i.p.	Day 1, QD 5 days	glucose GTT body weight survival	DYRK1B
	FX7742	[**]	po	*Day 12, QD 7 days
	6	6	STZ	[**]	i.p.	Day 1, QD 5 days	glucose GTT body weight survival	DYRK1B
	FX7742	[**]	po	*Day 12, QD 7 days

 

Note:
* The start of dosing for FX compounds and insulin in groups 3, 4, 5, and 6 will be started on a day mice [**].

 

     

     

    

 

		1.	N: number of animals in a group.

 

		2.	Dosing volume: adjust dosing volume based on body weight [**]

 

		3.	GTT (glucose dehydrogenase method, AlphaTRAK, Abbot Laboratories, Chicago, IL)

 

Study endpoints

 

The major endpoints of the study include the following:

 

		●	Body weight change

 

		●	GTT = Glucose Tolerance Test

 

		●	Insulin levels after treatments

 

		●	Survival

 

		●	Monitoring survival and glucose levels continues at least 1 week after
the last dose

 

Study 2 Design

 

Similar to Study 1 utilizing compound
FX8474, dose and schedule to be determined based on PK/PD and MTD studies for this compound.

Resources

 

		●	[**] studies will be conducted at Vilnius University Life Sciences
                                                                                                          Center, Department of Biological models.

 

		●	Bioanalytical analysis for PK samples of FX7742 will be conducted by Felicitex Therapeutics, MA

 

		●	IHC analysis of pancreas for an expression of Dyrkl B will also be conducted at Cureline, CA.

 

     

     

    

 

Quantities of Materials

 

		●	FX compounds to be provided by Felicitex.

 

		●	All other reagents to be provided by DolceRx

 

Communications

 

The Parties will discuss the progress
of the Research and share Research Data on a weekly basis, or as otherwise agreed. These discussions take place by telephone or Zoom.

 

Term

 

The Term of this Exhibit is the
earlier of (i) 2 months from the Effective Date or (ii) the delivery of all Research Data.

 

Timing

 

1
week to get animals in for PK and MTD studies.

1
week for in life PK (dosing, blood draws)

1 week bioanalytical at Felicitex

1-2 weeks[**] –
can be done in parallel with PK analysis

1-2 weeks [**](3-4weeks
from initiation of study) for monitoring efficacy

Total 6-8 weeks for
demonstration of efficacy [**].

 

Studies can be repeated and the design
of both Studies can be adjusted and modified according to mutual agreement between the parties.

 

     

     

    

 

Exhibit 2

The Purpose

 

Explore the potential of Felicitex’s
developed DYRK 1 inhibitors (FX 1610, FX7742, FX8474) in applications to [**].

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]